Carl-Magnus Högerkorp
Cyxone comments on clinical collaboration in the UK
Cyxone has entered into a research collaboration with a renowned British research group in Glasgow with the goal of conducting an exploratory phase...
Cyxone's CEO on plans for 2024
Cyxone's CEO Carl-Magnus Högerkorp is interviewed in BioStock's studio...
Cyxone identifies the target protein for rabeximod
Cyxone has a strong focus on the development of the lead candidate...
Cyxone's CEO on the issue: "This round will take us into early 2025"
Cyxone has had an eventful autumn, with new...
Cyxone on the issue and rabeximod's potential
Biotechnology company Cyxone is currently involved in a rights issue...
Issuance secures Cyxone's new strategy
In August, Cyxone announced a new strategy for...
Cyxone's CEO: "Strong expert support for our strategy"
A lot is happening in Cyxone during the fall of 2023....
Cyxone on the new strategy
Biotechnology company Cyxone recently announced that it is changing its strategy...
Update from Cyxone's new Chairman and CEO
Biotechnology company Cyxone has cancelled a number of activities...
Cyxone comments on the patent announcement from the US
Biotech company Cyxone is developing new therapies for the treatment of...
The pieces fall into place for Cyxone
Biotechnology company Cyxone recently released its fourth-quarter figures...
Cyxone's CEO on the current situation and pipeline
Malmö-based biotechnology company Cyxone is developing new treatments for autoimmune...